Dopamine (DA) functions as a neurotransmitter and hormone in humans and a wide variety of vertebrates and invertebrates. It is associated with emotional behavior, cognition, voluntary movement, motivation, punishment, and reward. Dopamine is produced in several brain areas, including the midbrain substrantia nigra (SN), VTA, and hypothalamus. The primary function of the midbrain SN DA system, termed the nigrostriatal system, is for initiating and terminating planned movement and involves DA neurons that project to the dorsal striatum; the VTA DA system, termed the mesolimbic system, is for motivation and involves DA neurons that originate in the midbrain VTA and project to the ventral striatum, otherwise known as the nucleus accumbens (NAc); and the hypothalamic DA system, whose function is to inhibit the release of prolactin from the anterior lobe of the pituitary. The nigrostriatal and mesolimbic DA systems exhibit analogous neurons, circuits, neurotransmitters, and receptors. The mesolimbic DA system (Koob, 1992; Bloom, 1993; Kalivas et al., 1993; Schultz et al., 1997) constitutes part of the brain reward system that has evolved for mediating natural motivated behaviors such as feeding (Phillips et al., 2003), drinking (Agmo et al., 1995), and drug reward [including alcohol reward (Koob, 1996)]. There is considerable evidence demonstrating that DA release in the NAc induces a motivational drive and that the DA signal is modulated by past experience of reward and punishment (Oleson et al., 2012; Howe et al., 2013). Mesolimbic DA is believed to be a teaching signal which codes the magnitude of aversive and rewarding stimuli (Howe et al., 2013). The mesolimbic dopamine (DA) circuit originates in the ventral tegmental area (VTA) of the midbrain and terminates in the nucleus accumbens (NAc) of the striatum. Dopamine release within the mesolimbic circuit has been implicated in both associative learning and motivation (Schultz, Apicella, & Ljungberg, 1993; Wise, 2004). Preferential increases in DA release within the NAc are a hallmark of drugs of abuse (Di Chiara & Imperato, 1988), literally a scalar index of reward, suggesting that the abuse potential of a drug is tied to its ability to increase DA release within the NAc. The prevailing view is that drugs are initially consumed for their positive reinforcing properties, but that over time the maintenance of drug seeking is driven by the ability of the drug to alleviate the symptoms of withdrawal (Koob, 2014; Koob & Le Moal, 1997; Koob & Volkow, 2010, 2016). This progression from positive to negative reinforcement is, at least in part, the result of changes within the mesolimbic DA system. Acute administration of most drugs of abuse increase DA release in the NAc (Di Chiara & Imperato, 1985; Imperato & Di Chiara, 1986; Yim & Gonzales, 2000) whereas chronic consumption results in a protracted decrease in NAc DA levels during withdrawal (Weiss et al., 1996). This protracted decrease in NAc DA levels creates a anhedonic state in which individuals are more likely to seek out and consume drugs to increase DA levels in the NAc and thus diminish the feelings of dysphoria. This is often referred to as the negative reinforcement properties of ethanol, or the “dark side” of addiction.
Dysregulated DA transmission has been implicated in the allostatic properties of drugs of abuse (Wise, 2004). The dogma is that any drug or behavior that increases midbrain DA neuron activity will be rewarding, and potentially addictive (Kalivas et al., 1993; Nestler, 2001; Kalivas & Volkow, 2005). However, the neurobiology of the addiction process certainly involves multiple, complex neural circuits including the mesolimbic DA system (Diana et al., 2008; Steffensen et al., 2008; Olsson et al., 2009; 2009). Notwithstanding the complexity, the prevailing view is that people consume drugs for their rewarding properties, which are mediated by this system. Drugs enhance DA release resulting in feelings of pleasure, euphoria, and well-being. The level of DA release by some drugs of abuse can be 10 times that produced by natural rewarding behaviors such as eating, drinking, and sex. However, the onslaught of DA release is transient and often results in adaptations including progressive, compensatory lowering of baseline DA levels. Addicts continue their cycle of abuse, in part, as a result of maladapted and depleted DA levels, resulting in feelings of anxiety and dysphoria that drives subsequent drug-seeking behavior. Although this model seems straightforward in concept, it is likely over-simplistic in scope, as DA release may only be one determinant of addiction, as the DA projection from the VTA to the NAc is only part of a larger motivational circuit that includes cortical and subcortical structures. Indeed, modifications in DA release may be an epiphenomenon of a larger maladaptive process involving multiple neuronal substrates and inputs. Regardless, tolerance accrues to repeated drug use, resulting ultimately in persistently lowered DA release in the NAc. Although addiction begins as a personal choice to consume a drug or other reinforcer, the motivation to continue to seek the reinforcing stimulus is influenced greatly by genetic, environmental and experiential factors, leading to a spiraling dysregulation of brain DA with intermittent exposure to the reinforcer. The emerging view is that the impaired homeostasis that accompanies the development of drug addiction may result from experience-dependent neuroadaptations that usurp normal synaptic transmission in this system (Hyman & Malenka, 2001; Hyman et al., 2006; Kauer & Malenka, 2007; Nugent & Kauer, 2008). This maladapted state is associated psychologically with anxiety and behaviorally with drug-seeking behavior. The severity of associated symptoms and signs can for some drugs of abuse like alcohol can be life-threatening and the re-dosing behavior can frequently lead to overdose and death. The addicting substances are typically nonspecific in stimulation and may also include overstimulation of selective central receptors in the pain pathway among others.
In the clinical management of addiction, various strategies to mitigate withdrawal symptoms are employed until the patient no longer experiences the craving and the symptoms have fully subsided. This may involve methods of titration, substitution, and even aversion. Among all of these approaches, signaling of anxiety as a subjective perception of worry, unease, and nervousness is a prodrome which must be ameliorated (Piper et al., 2011). Sometimes prescription drugs, for example in the benzodiazepine class, can mitigate this mind state. Multiple ancillary strategies have been showed to benefit, including acupuncture, yoga, hypnosis, and psychotherapy. However, it is apparent that intervention must be readily available, including the home environment, to be an effective bridge.
Bills, Steffensen et al (Bills et al., 2019) have recently showed in a mouse model that the central pathway of stimulation resulting in dopamine release can be controllably activated by peripheral mechanoreceptor stimulation, in some implementations optimally in the range of 45-80 Hz and predominantly at receptors in the cervical spine region. Such stimulation causes release of dopamine in the NA with a prolonged duration of many minutes beyond cessation, the so-called afterglow effect. It is reasonable to hypothesize that such physical stimulation can function as a benign, repeatable bridge through symptoms and signs of withdrawal. As such, an on-demand availability of a device to which a patient can resort while in withdrawal could immediately ameliorate symptoms and signs, but specifically prevent progression beyond anxiety.
To this end, the inventors have developed a device and method for introducing vibrations to patient as a way to reduce symptoms and anxiety to a patient. The system may include vibration contacts to introduce vibration, each contact driven by a vibration source. A first vibration contact may be in mechanical communication with a first location of the body of the patient. A first vibration source may be connected to the first vibration contact and configured to cause a first vibration of the first vibration contact. A second vibration contact may be in mechanical communication with a second location of the body of the patient. A second vibration source may be connected to the second vibration contact and configured to cause a second vibration of the second vibration contact. The location or orientation of the first vibration contact and the second vibration contact may be configured such that the first vibration combines with the second vibration to generate a super-imposed vibration that travels along the spine of the patient.
In one particular implementation, the system include a self-centering, conforming seat similar to a deep pan tractor seat. The seat may be divided into two halves in the sagittal plane such that the center of contact weight in the seated position is directly beneath each ischial tuberosity. On the underside of each of the seat halves may be affixed two low frequency effect (LFE) transducers which can be independently driven with various frequencies, amplitudes, and waveform shapes. By this method, interferential beat frequencies in the therapeutic range interact to provide subjectively localized maxima in a traveling pattern which can be focused in the cervical spine. The patient experiences relief of anxiety and feelings of relaxation. The subjective relief endures for many minutes post stimulation. The induced, non-displacing vibration and beat effects can be quantified for duration and compliance of use in a treatment regimen.
Yet further, recent studies from Martorell and Tsai (Martorell et al., 2019) have suggested additive therapeutic effects when other sensory modalities have been employed in cognitive enhancement in an animal model of Alzheimer's disease. Similarly, Clements-Cortex (Clements-Cortes et al., 2016) has showed that rhythmic visual and auditory stimulation may be beneficial to cognitive function. In disclosed system and method, the tactile activation of mechanoreceptors by vibration may be augmented in the brain by similarly entrained pulses in the visual and auditory systems. The system and method have also been adapted to induce synchronized multi-modality sensory input into the brain, including differential frequencies to induce the beat effect.
Turning now to
The system shown is configured to drive asymmetric, independent vibration into each half of the seat and the body. Two programmable function generators 312 may control each LFE transducer (e.g. 116, 118) independently. The programmable generators 312 can create a first drive signal 316 and a second drive signal 318. The first and second drive signals 316, 318 may be sinusoidal, triangular, a rectangular with variable duty cycle at frequencies, or a customized waveform between 5 and 200 Hz to correlate with the range limits of the LFE transducers. The output voltage of the function generators can be adjusted between 0 and 1.5 V, the latter for maximal drive effect. The first and second drive signals 316, 318 may be conditioned (e.g. amplified, strengthened, conditioned, increased in power) by an amplifier 314. Further, the waveform combinations between two simultaneously operating function generators can be sequenced in time to achieve various parameters in the desired frequency range of 45 to 80 Hz. Exemplary function generator may include the Resonant Light Progen II programmable function generators for this purpose (Resonant Light Technology Inc., Courtenay, BC).
Continuing with
A computer software oscilloscope rendering may be used to illustrate a real time plotting of inductive coil pickup voltages from the stereo LFE transducers. While sinusoidal drive in the optimal frequency range of 45-80 Hz range is can be easily induced, the effect is weak. An alternative approach has been showed to be more effective. Each LFE transducer may be driven with a rectangular square wave 510 with 50% duty cycle at a sequenced range between 15 and 26.7 Hz and 16 and 27.7 Hz respectively. Since the square wave is of high quality, the 3rd harmonic of transduced energy may be dominant in a range between 45 and 81 H. The plot in
Driving two stereo amplifiers with an offset frequency, in this instance 1 Hz, results in induced beat frequencies which represent the difference between the two drive frequencies. For example, 26.7 Hz in channel A and 27.7 Hz in channel B induces a sinusoidal 1 Hz beat frequency which consists of the two fundamental drive signals swelling and collapsing in a repeating pattern. When the two signals are fully out of phase, the subject experiences transverse oscillation of the hips in the conformal seat. When the two signals are fully in phase, the subject experiences vertical oscillation and vibration extending into the cervical spine and head. In transition between phases at the beat frequency, the subject experiences a vertical traversing wave with a maximum which can be phase-locked. For example, if maximal cervico-thoracic vibration is desirable, locking of the phase relationship 520 to 15 degrees achieves this. The super-imposed waveform produced 522 is shown in plot 5d.
A software rendering of a surround sound format is employed to depict the location of the maximal vibration as it traverses the spine from pelvis to cranium. Surround sound software allows 3 or more sources of sound in the auditory and infrasonic range to be depicted as a function of independently controlled or measured amplitude and phase. In this instance, the coronal plane of the body is portrayed as rendered in
In
Alternative, the professional can access the parameters in real time and adjust the parameters while simultaneously monitoring the treatment of the subject. The information recorded for each session may include vibration patterns, duration, and exercises. Additionally, the data collected regarding the vibration parameters may be integrated with other locally transduced or measured sensors known to respond to anxiety or withdrawal including heart rate, blood pressure, heart rate variability, skin DC resistance or impedance, or pupillary size and reactivity. These additional, measurements may be presented with the vibration measurements and may be used to manually or automatically adjust the vibration parameters (e.g. frequency, amplitude, phase, duration and waveform) for the waveform generators.
Modifications to these embodiments by use of alternative transducer and sensor types, methods of subject positioning for optimal engagement of peripheral sensorimotor mechanoreceptor circuits, data gathering and analysis, and co-registration with other biomarkers of anxiety may be familiar to those skilled in the diagnostic and therapeutic science and art of management of withdrawal. All are within the spirit and scope of these claims.
This application claims the benefit of U.S. Provisional Application No. 62/815,981, filed Mar. 8, 2019, U.S. Provisional Application No. 62/837,638, filed Apr. 23, 2019, and U.S. Provisional Application No. 62/863,160, filed Jun. 18, 2019, the contents of which are hereby incorporated by reference. This application is a 371 national phase of PCT/US2020/029626, filed Apr. 23, 2020, and claims the benefit of U.S. Provisional Application No. 62/815,981, filed Mar. 8, 2019, U.S. Provisional Application No. 62/837,638, filed Apr. 23, 2019, and U.S. Provisional Application No. 62/863,160, filed Jun. 18, 2019, the contents of which are hereby incorporated by reference.
This invention was made with government support under Grant Numbers AA020919, DA035958 and F32AT009945 awarded by the National Institutes of Health. The government has certain rights in the invention.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2020/029626 | 4/23/2020 | WO |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2020/186274 | 9/17/2020 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
4105024 | Raffel | Aug 1978 | A |
4570616 | Kunz | Feb 1986 | A |
4920583 | Hough | May 1990 | A |
5020518 | Spears | Jun 1991 | A |
5857986 | Moriyasu | Jan 1999 | A |
6087942 | Sleichter, III | Jul 2000 | A |
6319213 | Tomac | Nov 2001 | B1 |
7311681 | Vaccarella | Dec 2007 | B1 |
7553288 | Cohen | Jun 2009 | B2 |
7614099 | Goetz | Nov 2009 | B2 |
7771375 | Nishibori | Aug 2010 | B2 |
9457166 | Lasorso, Jr. | Oct 2016 | B1 |
9549867 | El-Messeiry | Jan 2017 | B1 |
9943461 | Muench | Apr 2018 | B1 |
20020183667 | Kitadou | Dec 2002 | A1 |
20030060741 | Park | Mar 2003 | A1 |
20050054958 | Hoffmann | Mar 2005 | A1 |
20080070752 | Einav | Mar 2008 | A1 |
20080195007 | Podrazhansky et al. | Aug 2008 | A1 |
20090250982 | Cohen | Oct 2009 | A1 |
20100036297 | Kim | Feb 2010 | A1 |
20100265090 | Bisset | Oct 2010 | A1 |
20110028869 | Imai | Feb 2011 | A1 |
20120022348 | Droitcour et al. | Jan 2012 | A1 |
20130210577 | Ceoldo | Aug 2013 | A1 |
20130281897 | Hoffmann | Oct 2013 | A1 |
20130345602 | Yang | Dec 2013 | A1 |
20140018713 | Elenga | Jan 2014 | A1 |
20140058288 | Bartol | Feb 2014 | A1 |
20150173669 | Simon | Jun 2015 | A1 |
20150182418 | Zaiss | Jul 2015 | A1 |
20150305975 | Maffei | Oct 2015 | A1 |
20170182324 | Carroll | Jun 2017 | A1 |
20170333005 | Chen et al. | Nov 2017 | A1 |
20170348180 | Inada | Dec 2017 | A1 |
20180036198 | Mergl | Feb 2018 | A1 |
20180042627 | Gilstad et al. | Feb 2018 | A1 |
20180200519 | Walker et al. | Jul 2018 | A1 |
20190105517 | Tyler | Apr 2019 | A1 |
20190299832 | Uenal | Oct 2019 | A1 |
20200085673 | Seo | Mar 2020 | A1 |
20200246579 | Cohen | Aug 2020 | A1 |
20200330322 | Kang | Oct 2020 | A1 |
Number | Date | Country |
---|---|---|
107468499 | Dec 2017 | CN |
1688119 | Aug 2006 | EP |
2342103 | Apr 2000 | GB |
100757294 | Feb 2007 | KR |
Entry |
---|
Cambridge Dictionary, Definition of Stereo, 2022. (Year: 2022). |
Virtins Technology, “Multi-Instrument—Spectrum 3D Plot,” Jan. 22, 2016. (Year: 2016). |
Written Opinion issued on Aug. 10, 2020, in PCT/US2020/29626. |
International Search Report issued on Aug. 10, 2020, in PCT/US2020/29626. |
Koob, George F.; “Dopamine, addiction and reward”; Seminars in The Neurosciences; 1992; vol. 4; pp. 139-148. |
Schultz, Wolfram, et al.; “A Neural Substrate of Prediction and Reward”; Science ; Mar. 14, 1997; New Series; vol. 275, No. 5306; pp. 1593-1599. |
Phillips, Anthony G., et al.; “Amygdalar control of the mesocorticolimbic dopamine system: parallel pathways to motivated behavior”; Neuroscience and Biobehavioral Reviews; 2003; 27; pp. 543-554. |
Agmo, Anders, et al. ; “Reward and Reinforcement Produced by Drinking Sucrose: Two Processes That May Depend on Different Neurotransmitters”; Pharmacology Biochemistry and Behavior; 1995; vol. 52, No. 2; pp. 403-414. |
Oleson, Erik B. ,et al.; “Subsecond Dopamine Release in the Nucleus Accumbens Predicts Conditioned Punishment and its Successful Avoidance”; The Journal of Neuroscience; Oct. 17, 2012; 32(42); pp. 14804 -14808. |
Howe, Mark W.; “Prolonged dopamine signalling in striatum signals proximity and value of distant rewards”; Nature; Research Letter; Aug. 29, 213; vol. 500; pp. 575-590; doi:10.1038/nature12475. |
Schultz, Wolfram, et al.; “Responses of Monkey Dopamine Neurons to Reward and Conditioned Stimuli during Successive Steps of Learning a Delayed Response Task”; The Journal of Neuroscience; Mar. 1993; 13(3); pp. 900-913. |
Di Chiara, Gaetano, et al.; “Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats”; Neurobiology; Proc. Natl. Acad. Sci.; Jul. 1988; vol. 85; pp. 5274-5278. |
Le Moal, Michel, et al.; “Drug addiction: Pathways to the disease and pathophysiological perspectives”; European Neuropsychopharmacology; 2007; 17; pp. 377-393. |
Koob, George F., et al.; “Neurocircuitry of Addiction”; Neuropsychopharmacology Reviews; 2010; 35; pp. 217-238. |
Koob, George F., et al.; “Neurobiology of addiction: a neurocircuitry analysis”; Lancet Psychiatry; Aug. 2016; 3(8); pp. 760-773; doi:10.1016/S2215-0366(16)00104-8. |
Imperato, Assunta, et al.; “Dopamine Release and Metabolism in Awake Rats After Systemic Neuroleptics as Studied by Trans-Striatal Dialysis”; The Journal of Neuroscience; Feb. 1985; vol. 5, No. 2; pp. 297-306. |
Yim, Hyeon Joo, et al.; “Ethanol-induced increases in dopamine extracellular concentration in rat nucleus accumbens are accounted for by increased release and not uptake inhibition”; Alcohol; 2000; 22; pp. 107-115. |
Weiss, Friedbert, et al.; “Ethanol Self-Administration Restores Withdrawal-Associated Deficiencies in Accumbal Dopamine and 5-Hydroxytryptamine Release in Dependent Rats”; The Journal of Neuroscience; May 15, 1996; 16(10); pp. 3474-3485. |
Nestler, Eric J.; “Psychogenomics: Opportunities for Understanding Addiction”; The Journal of Neuroscience; Nov. 1, 2001; 21(21); pp. 8324-8327. |
Kalivas, Peter W., et al.; “The Neural Basis of Addiction: A Pathology of Motivation and Choice”; Am J Psychiatry; Aug. 2005; 162:8; pp. 1403-1413. |
Marco, Diana, et al.; “Crucial Role of Acetaldehyde in Alcohol Activation of the Mesolimbic Dopamine System”; Ann. N. Y. Acad. Sci. 1139: 307-317 (2008). 2008 New York Academy of Sciences; doi: 10.1196/annals.1432.009. |
Steffensen, Scott C., et al.; “Cocaine disinhibits dopamine neurons in the ventral tegmental area via use-dependent plockade of GABA neuron voltage-sensitive sodium channels”; European Journal of Neuroscience; 2008; vol. 28; pp. 2028-2040; doi:10.1111/j.1460-9568.2008.06479.x. |
Olsson, Sara K., et al.; “Elevated levels of kynurenic acid change the dopaminergic response to amphetamine: Implications for schizophrenia”; International Journal of Neuropsychopharmacology; 2009; 12; pp. 501-512; doi:10.1017/S1461145708009383. |
Hyman, Steven E., et al.; “Addiction and the Brain: the Neurobiology of Compulsion and its Persistence”; Neuroscience; Nature Reviews; Oct. 2001; vol. 2; pp. 695-703. |
Hyman, Steve E., et al.; “Neural Mechanisms of Addiction: The Role of Reward-Related Learning and Memory”; Neural Mechanisms of Addiction; Annu. Rev. Neurosci. 2006.29:565-598. Downloaded from www.annualreviews.org. |
Nugent, Fereshteh S., et al.; “LTP of GABAergic synapses in the ventral tegmental area and beyond”; J Physiol; 2008; 586.6; pp. 1487-1493. |
Piper, Megan E., et al.; “Anxiety Diagnoses in Smokers Seeking Cessation Treatment: Relations with Tobacco Dependence, Withdrawal, Outcome, and Response to Treatment”; Addiction; Feb. 2011; 106(2); pp. 418-427; doi:10.1111/j.1360-0443.2010.03173.x. |
Bills, Kyle B., et al.; “Targeted Subcutaneous Vibration With Single-Neuron Electrophysiology as a Novel Method for Understanding the Central Effects of Peripheral Vibrational Therapy in a Rodent Model”; Dose-Response: An International Journal; Jan.-Mar. 2019; pp. 1-7. |
Martorell, Anthony J., et al.; “Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition”; Cell; Apr. 4, 2019; 177; pp. 256-271; https://doi.org/10.1016/j.cell.2019.02.014. |
Clements-Cortes A, Ahonen H, Evans M, Freedman M, Bartel L (2016). Journal of Alzheimer's Disease, 52(2), 651-660. DOI 10.3233/JAD-160081. ref Ko et al. |
International Preliminary Report on Patentability received for PCT Patent Application No. PCT/US2020/029626, mailed on Sep. 23, 2021, 07 pages. |
Number | Date | Country | |
---|---|---|---|
20220183925 A1 | Jun 2022 | US |
Number | Date | Country | |
---|---|---|---|
62863160 | Jun 2019 | US | |
62837638 | Apr 2019 | US | |
62815981 | Mar 2019 | US |